As we’ve already seen, Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. Innovative Medicines contributed ~67.4% of Novartis’s total revenues in Q2 2018, a 10% growth YoY (year-over-year) to $8.9 billion.
The above chart compares the revenues for Innovative Medicines since the first quarter of 2017. Let’s look next at franchise product revenues.
Ophthalmology products reported a 1% decrease in revenues YoY to ~$1.2 billion in Q2 2018, driven by lower sales of products from the Topical Olopatadine group, the Travoprost group, and other products, partially offset by strong sales of Lucentis.
Neuroscience products reported a 3% growth in revenues YoY to $889 million in Q2 2018 following strong sales for Gilenya.
Immunology, hepatology, and dermatology products reported a 41% growth in revenues YoY to $833 million in Q2 2018 following strong sales of Cosentyx and Ilaris.
Respiratory products reported a 14% growth in revenues YoY to $433 million in Q2 2018 following strong sales of Seebri Breezhaler, Ultibro Breezhaler, Xolair, and other respiratory products, partially offset by lower sales of Onbrez Breezhaler.
Cardiometabolic products reported ~100% growth in revenues YoY to $245 million in Q2 2018, driven by strong sales of Entresto and other products.
Established products reported a 1% decline in revenues YoY to $1.8 billion in Q2 2018.
Oncology products reported a 12% growth in revenues YoY to $3.4 billion in Q2 2018, driven by strong sales of Tafinlar and Mekinist, Tasigna, Afinitor/Votubia, Promacta/Revolade, Votrient, Exjade/Jadenu, Kisqali, Jakavi, and Kymriah, substantially offset by lower sales of Gleevec/Glivec, Sandostatin, and other oncology products.
The Invesco BLDRS Developed Markets 100 ADR ETF (ADRD) holds 5.3% of its total investments in Novartis ADR (NVS), 2.5% in GlaxoSmithKline ADR (GSK), 2.5% in Sanofi ADR (SNY), and 2.4% in AstraZeneca ADR (AZN).